Key Drivers
- Margin strength
- Cash rich
- High valuation
AIAI Summary
Veeva now looks more like a high-quality compounder than a cheap healthcare software stock: strong cash generation, sticky recurring revenue, and AI-enabled workflow expansion support the upside, but with a rich multiple, rising Salesforce competition, and weak near-term price action, investors need clear proof of Vault CRM/AI adoption before expecting re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin strength
- •Cash rich
- •High valuation
VEEV shows high-quality, highly profitable growth with strong cash generation and a fortress balance sheet, but its rich valuation and heavy stock-based compensation limit near-term upside.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Failed rally
- •Support holding
VEEV is in a short-term downtrend over the last month, with lower highs and failed rallies keeping sellers in control unless it reclaims $160 and then $166-$172, while $155-$156 remains the key support zone.
Rally to $171.60 on 2026-05-01 failed quickly, then price briefly fell below $160 on 2026-05-12
Sentiment & News
Key News Insights:
- •Index inclusion
- •AI expansion
- •Mixed performance
Veeva is gaining visibility from S&P 500 inclusion, AI-led product expansion, and new Roche/BioMarin/Smith+Nephew partnerships, even as the stock has shown mixed near-term performance.
#S&P500
The headlines are constructive for VEEV's long-term growth narrative, but near-term sentiment may stay uneven until execution and earnings confirm momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings